Low low-density lipoprotein cholesterol (LDL-C) levels are associated with a reduced risk for dementia, including Alzheimer ...

The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) ...

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, ...

A single dose of an siRNA molecule reduces elevated lipoprotein(a) — a major, but to date, largely untreatable risk factor ...

Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting ...

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

If you have high levels of 'bad' cholesterol, you typically won't see any symptoms, making it a silent but dangerous risk ...

UVA professor Dr. Christopher Kramer explains how a new Eli Lilly drug may cut a significant heart attack risk factor by 95%.

Lipoprotein a (Lp[a]) is a valuable tool for assessing a patient's risk of cardiovascular disease, which can facilitate earlier intervention efforts and reduce health care costs, argued Jeremy ...

High intake of ultra-processed foods is linked to adverse metabolic health and microstructural brain changes in regions that ...

The 5:2 diet effectively reduces weight, BMI, and LDL while improving cardiometabolic health in patients with overweight or obesity, per a meta-analysis.